Allogeneic and other innovative chimeric antigen receptor platforms
By Andrew P Jallouk, Salyka Sengsayadeth & 3 more. Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies. All of the CAR T-cell products that are currently FDA-approved are autologous.
Authors
- Andrew Philip Jallouk (ORCID: https://orcid.org/0000-0003-4335-7942)
- Olalekan O. Oluwole (ORCID: https://orcid.org/0000-0001-8525-9641)
- Bhagirathbhai Dholaria (ORCID: https://orcid.org/0000-0003-2371-3655)
- Salyka Sengsayadeth
- Bipin N. Savani (ORCID: https://orcid.org/0000-0002-3304-9965)
Institutions
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Clinical Hematology International
- Published
- 2024-09-27
- DOI
- https://doi.org/10.46989/001c.121404
- Citations
- 6
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.70